JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in <svg     style="vertical-align:-0.26999pt;width:52.549999px;" id="M1" height="18.9125" version="1.1" viewBox="0 0 52.549999 18.9125" width="52.549999"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.022,-0,0,-.022,.062,18.513)"><path id="x43" d="M614 175l29 -10q-33 -109 -57 -154q-121 -26 -184 -26q-90 0 -160.5 29t-112.5 77t-63.5 105.5t-21.5 119.5q0 157 108 253t277 96q36 0 71.5 -5t69 -13.5t36.5 -8.5q15 -102 20 -150l-29 -8q-20 79 -66.5 114t-128.5 35q-119 0 -187.5 -86t-68.5 -207
q0 -140 73.5 -227.5t188.5 -87.5q73 0 119.5 37.5t86.5 116.5z" /></g><g transform="matrix(.022,-0,0,-.022,14.969,18.513)"><path id="x44" d="M43 650h280q194 0 282 -85q85 -82 85 -215q0 -173 -123 -267q-107 -83 -297 -83h-236v27q65 5 79.5 19.5t14.5 77.5v402q0 45 -6 62.5t-21.5 24t-57.5 9.5v28zM213 547v-416q0 -55 24.5 -75t81.5 -20q133 0 203 86t70 214q0 80 -30 143t-88 97q-66 41 -170 41
q-62 0 -78 -13q-13 -9 -13 -57z" /></g><g transform="matrix(.022,-0,0,-.022,31.445,18.513)"><path id="x1D7D6" d="M472 187q0 -91 -62.5 -145.5t-169.5 -54.5q-97 0 -154.5 46t-57.5 124q0 132 149 168q-74 44 -106 87.5t-32 100.5q0 80 60.5 127.5t163.5 47.5q89 0 142 -40.5t53 -104.5q0 -98 -136 -140q84 -57 117 -105t33 -111zM339 537q0 54 -23.5 88t-64.5 34q-35 0 -59 -24
t-24 -59q0 -87 130 -154q25 33 33 56t8 59zM333 127q0 54 -26 89q-26 36 -107 90q-51 -75 -51 -145q0 -68 24 -105t69 -37q42 0 66.5 28.5t24.5 79.5z" /></g>

			<g transform="matrix(.016,-0,0,-.016,42.65,7.75)"><path id="x2B" d="M535 230h-212v-233h-58v233h-213v50h213v210h58v-210h212v-50z" /></g>

		
	
</svg> T Cells in Renal Cell Carcinoma Patients

<table>Cell cycle analysis of responder-CD8<sup>+</sup> T cells after MLTC<i>.</i> Cellular DNA content was analyzed in three RCC patients and their HLA-matched normal donors by flow cytometry, with data analyzed on WinMDI version 2.8 software.</table>

BioMed Research International

fig5

Figure 5

Figure 5: JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in <svg     style="vertical-align:-0.26999pt;width:52.549999px;" id="M1" height="18.9125" version="1.1" viewBox="0 0 52.549999 18.9125" width="52.549999"  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg">
	
		
			<g transform="matrix(.022,-0,0,-.022,.062,18.513)"><path id="x43" d="M614 175l29 -10q-33 -109 -57 -154q-121 -26 -184 -26q-90 0 -160.5 29t-112.5 77t-63.5 105.5t-21.5 119.5q0 157 108 253t277 96q36 0 71.5 -5t69 -13.5t36.5 -8.5q15 -102 20 -150l-29 -8q-20 79 -66.5 114t-128.5 35q-119 0 -187.5 -86t-68.5 -207
q0 -140 73.5 -227.5t188.5 -87.5q73 0 119.5 37.5t86.5 116.5z" /></g><g transform="matrix(.022,-0,0,-.022,14.969,18.513)"><path id="x44" d="M43 650h280q194 0 282 -85q85 -82 85 -215q0 -173 -123 -267q-107 -83 -297 -83h-236v27q65 5 79.5 19.5t14.5 77.5v402q0 45 -6 62.5t-21.5 24t-57.5 9.5v28zM213 547v-416q0 -55 24.5 -75t81.5 -20q133 0 203 86t70 214q0 80 -30 143t-88 97q-66 41 -170 41
q-62 0 -78 -13q-13 -9 -13 -57z" /></g><g transform="matrix(.022,-0,0,-.022,31.445,18.513)"><path id="x1D7D6" d="M472 187q0 -91 -62.5 -145.5t-169.5 -54.5q-97 0 -154.5 46t-57.5 124q0 132 149 168q-74 44 -106 87.5t-32 100.5q0 80 60.5 127.5t163.5 47.5q89 0 142 -40.5t53 -104.5q0 -98 -136 -140q84 -57 117 -105t33 -111zM339 537q0 54 -23.5 88t-64.5 34q-35 0 -59 -24
t-24 -59q0 -87 130 -154q25 33 33 56t8 59zM333 127q0 54 -26 89q-26 36 -107 90q-51 -75 -51 -145q0 -68 24 -105t69 -37q42 0 66.5 28.5t24.5 79.5z" /></g>

			<g transform="matrix(.016,-0,0,-.016,42.65,7.75)"><path id="x2B" d="M535 230h-212v-233h-58v233h-213v50h213v210h58v-210h212v-50z" /></g>

		
	
</svg> T Cells in Renal Cell Carcinoma Patients 

BioMed Research International

JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in T Cells in Renal Cell Carcinoma Patients

Figure 5